Volume 33, Issue 157 (March & April 2025)                   J Adv Med Biomed Res 2025, 33(157): 3-3 | Back to browse issues page

Ethics code: IR.BUMS.REC.1400.319

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Siami-Aliabad M, Moradi N, Tavakoli T, Salmani F, Ranjbaran J, Safarpour H et al . Exploring the Diagnostic Potential of hsa-circRNA-001587 and hsa-circ-0004872 in Colorectal Cancer: A Population-Based Diagnostic Approach. J Adv Med Biomed Res 2025; 33 (157) :3-3
URL: http://journal.zums.ac.ir/article-1-7539-en.html
Exploring the Diagnostic Potential of hsa-circRNA-001587 and hsa-circ-0004872 in Colorectal Cancer: A Population-Based Diagnostic Approach
Mahin Siami-Aliabad1 , Nariman Moradi2 , Tahmine Tavakoli3 , Fatemeh Salmani4 , Javad Ranjbaran5 , Hossein Safarpour6 , Elham Chamani *7
1- Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran & Department of Clinical Biochemistry, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
2- Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
3- Geriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran
4- Geriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran & Department of Epidemiology and Biostatistics, Social Determinants of Health Research Center, Faculty of Health, Birjand University of Medical Sciences, Birjand, Iran
5- Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
6- Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran & Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
7- Department of Clinical Biochemistry, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran & Geriatric Health Research Center, Birjand University of Medical Sciences, Birjand, Iran , chamani.elham@bums.ac.ir
Abstract:   (119 Views)

Background and Aims: Colorectal cancer contributes substantially to global cancer mortality, ranking among the leading causes of cancer-related deaths. Studies have linked its development to diminished expression of the SLC4A4 gene alongside elevated levels of the microRNAs hsa-miR-223-3p and hsa-miR-106a-5p. This study examines hsa-circRNA-001587 and hsa-circ-0004872 to determine their utility as population-based markers for colorectal cancer detection. By focusing on these circRNAs, the investigation aims to contribute valuable insights into CRC diagnostics.
Methods: This investigation leveraged population-based data by retrieving thirty matched pairs of colorectal carcinoma and adjacent non-tumoral tissues from patients at Shahid Beheshti University of Medical Sciences and Valiasr Hospital in Birjand, Iran. Systematic patient recruitment, comprehensive data collection, and rigorous tissue sample procedures were employed. RNA extraction and analysis focused on hsa-circRNA-001587 and hsa-circ-0004872, with validation carried out through reverse transcription qPCR and Sanger sequencing.
Results: Our findings indicated that hsa-circRNA-001587 and hsa-circ-0004872 were reduced by 1.34-fold and 2.19-fold, respectively, in CRC specimens compared with matched adjacent non-tumorous tissues, although these differences did not reach statistical significance (p > 0.05). Furthermore, our statistical analysis demonstrated a robust and significant link between hsa-circ-0004872 and hsa-circRNA-001587, suggesting that an increase in one corresponds consistently with an increase in the other (p-value ≤ 0.001, r = 0.81).
Conclusion: Although the non-significant downregulation-likely reflecting our small sample size-suggests caution, hsa-circ-0004872 and hsa-circRNA-001587 probably act as tumor suppressors via the hsa-circ-0004872/hsa-circRNA-001587/hsa-miR-223-3p/hsa-miR-106a-5p/SLC4A4 axis, warranting further evaluation in serum and plasma as CRC diagnostic markers and therapeutic targets.

Keywords: Colorectal Cancer, Biomarker, hsa-circRNA-001587, hsa-circ-0004872
     
Type of Study: Original Research Article | Subject: Clinical Medicine
Received: 2025/01/21 | Accepted: 2025/04/28 | Published: 2025/05/29
References
1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233-54. [DOI:10.3322/caac.21772] [PMID]
2. Pisignano G, Michael DC, Visal TH, Pirlog R, Ladomery M, Calin GA. Going circular: history, present, and future of circRNAs in cancer. Oncogene. 2023;42(38):2783-800. [DOI:10.1038/s41388-023-02780-w] [PMID] [PMCID]
3. Aljama S, Lago EP, Zafra O, Sierra J, Simón D, Santos C, et al. Dichotomous colorectal cancer behaviour. Crit Rev Oncol Hematol. 2023;189:104067. [DOI:10.1016/j.critrevonc.2023.104067] [PMID]
4. Farc O, Budisan L, Berindan-Neagoe I, Braicu C, Zanoaga O, Zaharie F, et al. A Group of Tumor-Suppressive micro-RNAs Changes Expression Coordinately in Colon Cancer. Curr Issues Mol Biol. 2023;45(2):975-89. [DOI:10.3390/cimb45020063] [PMID] [PMCID]
5. Zhu X, Jin X, Li Z, Chen X, Zhao J. miR-152-3p facilitates cell adhesion and hepatic metastases in colorectal cancer via targeting AQP11. Pathol Res Pract. 2023;244:154389. [DOI:10.1016/j.prp.2023.154389] [PMID]
6. Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19(1):47. https://doi.org/10.1186/s12943-020-01171-z [DOI:10.1186/s12943-022-01530-y] [PMID] [PMCID]
7. Babin L, Andraos E, Fuchs S, Pyronnet S, Brunet E, Meggetto F. From circRNAs to fusion circRNAs in hematological malignancies. JCI Insight. 2021;6(21):e151513. [DOI:10.1172/jci.insight.151513] [PMID] [PMCID]
8. Dawoud A, Ihab Zakaria Z, Hisham Rashwan H, Braoudaki M, Youness RA. Circular RNAs: New layer of complexity evading breast cancer heterogeneity. Noncoding RNA Res. 2023;8(1):60-74. [DOI:10.1016/j.ncrna.2022.09.011] [PMID] [PMCID]
9. Zhou W-Y, Cai Z-R, Liu J, Wang D-S, Ju H-Q, Xu R-H. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19:1-19. [DOI:10.1186/s12943-020-01286-3] [PMID] [PMCID]
10. Brown JR, Chinnaiyan AM. The Potential of Circular RNAs as Cancer Biomarkers. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2541-55. [DOI:10.1158/1055-9965.EPI-20-0796] [PMID]
11. Lyu L, Zhang S, Deng Y, Wang M, Deng X, Yang S, et al. Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer. J Hematol Oncol. 2021;14(1):41. [DOI:10.1186/s13045-021-01052-y] [PMID] [PMCID]
12. Hue SS, Jin Y, Cheng H, Bin Masroni MS, Tang LWT, Ho YH, et al. Tissue-Specific microRNA Expression Profiling to Derive Novel Biomarkers for the Diagnosis and Subtyping of Small B-Cell Lymphomas. Cancers (Basel). 2023;15(2):453. [DOI:10.3390/cancers15020453] [PMID] [PMCID]
13. He Z, Zhu Q. Circular RNAs: Emerging roles and new insights in human cancers. Biomed Pharmacother. 2023;165:115217. [DOI:10.1016/j.biopha.2023.115217] [PMID]
14. Zhang Y, Luo J, Yang W, Ye WC. CircRNAs in colorectal cancer: potential biomarkers and therapeutic targets. Cell Death Dis. 2023;14(6):353. [DOI:10.1038/s41419-023-05881-2] [PMID] [PMCID]
15. Hashemi M, Khosroshahi EM, Daneii P, Hassanpoor A, Eslami M, Koohpar ZK, et al. Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response. Noncoding RNA Res. 2025;10:98-115. [DOI:10.1016/j.ncrna.2024.09.006] [PMID] [PMCID]
16. He YD, Tao W, He T, Wang BY, Tang XM, Zhang LM, et al. A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/mL at initial biopsy. Mol Cancer. 2021;20(1):96. [DOI:10.1186/s12943-021-01388-6] [PMID] [PMCID]
17. Wang Z, Deng H, Jin Y, Luo M, Huang J, Wang J, et al. Circular RNAs: biology and clinical significance of breast cancer. RNA Biol. 2023;20(1):859-74. [DOI:10.1080/15476286.2023.2272468] [PMID] [PMCID]
18. Yang J, Chen Z, He J, Zhao Y, Zhou C, Zhao X, et al. A circRNA-based ceRNA network shows its diagnostic value in non-small-cell lung cancer. Clin Biochem. 2023;121-122:110657. [DOI:10.1016/j.clinbiochem.2023.110657] [PMID]
19. Yi Q, Yue J, Liu Y, Shi H, Sun W, Feng J, et al. Recent advances of exosomal circRNAs in cancer and their potential clinical applications. J Transl Med. 2023;21(1):516. [DOI:10.1186/s12967-023-04348-4] [PMID] [PMCID]
20. Afzal S, Hassan M, Ullah S, Abbas H, Tawakkal F, Khan MA. Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications. Front Mol Biosci. 2022;9:783450. [DOI:10.3389/fmolb.2022.783450] [PMID] [PMCID]
21. Lim MCJ, Baird AM, Aird J, Greene J, Kapoor D, Gray SG, et al. RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies. Diagnostics (Basel). 2018;8(3):60. [DOI:10.3390/diagnostics8030060] [PMID] [PMCID]
22. Nomiri S, Hoshyar R, Chamani E, Rezaei Z, Salmani F, Larki P, et al. Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study. Biomed Pharmacother. 2022;147:112691. [DOI:10.1016/j.biopha.2022.112691] [PMID]
23. Ranjbaran J, Safarpour H, Nomiri S, Tavakoli T, Rezaei Z, Salmani F, et al. Experimental validation of in silico analysis estimated the reverse effect of upregulated hsa-miR-106a-5p and hsa-miR-223-3p on SLC4A4 gene expression in Iranian patients with colorectal adenocarcinoma by RT-qPCR. Cancer Med. 2023;12(6):7005-18. [DOI:10.1002/cam4.5499] [PMID] [PMCID]
24. Zhang X, Tan P, Zhuang Y, Du L. hsa_circRNA_001587 upregulates SLC4A4 expression to inhibit migration, invasion, and angiogenesis of pancreatic cancer cells via binding to microRNA-223. Am J Physiol Gastrointest Liver Physiol. 2020;319(6):G703-g17. [DOI:10.1152/ajpgi.00118.2020] [PMID]
25. Ma C, Wang X, Yang F, Zang Y, Liu J, Wang X, et al. Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit. Mol Cancer. 2020;19(1):157. [DOI:10.1186/s12943-020-01268-5] [PMID] [PMCID]
26. Xi L, Liu Q, Zhang W, Luo L, Song J, Liu R, et al. Circular RNA circCSPP1 knockdown attenuates doxorubicin resistance and suppresses tumor progression of colorectal cancer via miR-944/FZD7 axis. Cancer Cell Int. 2021;21(1):153. [DOI:10.1186/s12935-021-01855-6] [PMID] [PMCID]
27. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. [DOI:10.1016/j.tranon.2021.101174] [PMID] [PMCID]
28. Mo S, Dai W, Wang H, Lan X, Ma C, Su Z, et al. Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: A multicentre cohort study. EClinicalMedicine. 2023;55:101717. [DOI:10.1016/j.eclinm.2022.101717] [PMID] [PMCID]
29. Viralippurath Ashraf J, Sasidharan Nair V, Saleh R, Elkord E. Role of circular RNAs in colorectal tumor microenvironment. Biomed Pharmacother. 2021;137:111351. [DOI:10.1016/j.biopha.2021.111351] [PMID]
30. Li Z, Li X, Xu D, Chen X, Li S, Zhang L, et al. An update on the roles of circular RNAs in osteosarcoma. Cell Prolif. 2021;54(1):e12936. [DOI:10.1111/cpr.12936] [PMID] [PMCID]
31. Li Y, Gong L, Qin N, Wei X, Miao L, Yuan H, et al. Comprehensive analysis of circRNA expression pattern and circRNA-miRNA-mRNA network in oral squamous cell carcinoma. Oral Oncol. 2021;121:105437. [DOI:10.1016/j.oraloncology.2021.105437] [PMID]
32. Ning J, Luo Y, Chen L, Xiao G, Tanzhu G, Zhou R. CircRNAs and lung cancer: Insight into their roles in metastasis. Biomed Pharmacother. 2023;166:115260. [DOI:10.1016/j.biopha.2023.115260] [PMID]
33. Huang G, Liang M, Liu H, Huang J, Li P, Wang C, et al. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway. Cell Death Dis. 2020;11(12):1065. [DOI:10.1038/s41419-020-03276-1] [PMID] [PMCID]
34. Tang C, He X, Jia L, Zhang X. Circular RNAs in glioma: molecular functions and pathological implications. Non-Coding Rna Res. 2024;9(1):105-15. [DOI:10.1016/j.ncrna.2023.10.007] [PMID] [PMCID]
35. Song X, Zhang G, Niu J, Liu H, Li C, Ning W, et al. Circular RNA circPFKP suppress gastric cancer progression through targeting miR-346/CAMD3 axis. Exp Cell Res. 2025;445(1):114390. [DOI:10.1016/j.yexcr.2024.114390] [PMID]
36. Zhang F, Li L, Fan Z. circRNAs and their relationship with breast cancer: a review. World J Surg Oncol. 2022;20(1):373. [DOI:10.1186/s12957-022-02842-5] [PMID] [PMCID]
37. Cheng F, Zheng B, Si S, Wang J, Zhao G, Yao Z, et al. The Roles of CircRNAs in Bladder Cancer: Biomarkers, Tumorigenesis Drivers, and Therapeutic Targets. Front Cell Dev Biol. 2021;9:666863. [DOI:10.3389/fcell.2021.666863] [PMID] [PMCID]
38. Xiao W, Wang X, Wang T, Xing J. MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma. Aging (Albany NY). 2019;11(2):615-33. [DOI:10.18632/aging.101763] [PMID] [PMCID]
39. Barbagallo D, Ponti D, Bassani B, Bruno A, Pulze L, Akkihal SA, et al. MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces. Int J Mol Sci. 2024;25(15):8191. [DOI:10.3390/ijms25158191] [PMID] [PMCID]
40. Dai Y, Zhu Y, Xu H. circ_0004872 inhibits proliferation, invasion, and glycolysis of oral squamous cell carcinoma by sponged miR-424-5p. J Clin Lab Anal. 2022;36(7):e24486. [DOI:10.1002/jcla.24486] [PMID] [PMCID]
41. Zhang GJ, Zhou H, Xiao HX, Li Y, Zhou T. Up-regulation of miR-224 promotes cancer cell proliferation and invasion and predicts relapse of colorectal cancer. Cancer Cell Int. 2013;13(1):104. [DOI:10.1186/1475-2867-13-104] [PMID] [PMCID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb